Vidarabine Monophosphate Market Size, Share, Growth, and Industry Analysis, By Type (0.1G, 0.2G), By Application (Chronic Hepatitis B, Hand, Foot and Mouth Disease, Viral Infection, Other), Regional Insights and Forecast to 2035

Vidarabine Monophosphate Market Overview

The global Vidarabine Monophosphate Market size estimated at USD 1267.06 million in 2026 and is projected to reach USD 1971.46 million by 2035, growing at a CAGR of 5.04% from 2026 to 2035.

The Vidarabine Monophosphate Market is witnessing significant expansion due to increasing antiviral drug manufacturing activities, rising prevalence of viral infections, and growing pharmaceutical research initiatives across biotechnology laboratories and contract manufacturing organizations. Vidarabine monophosphate is widely utilized in antiviral formulations targeting herpes simplex and varicella-zoster infections, supporting broader pharmaceutical demand. More than 48% of antiviral API manufacturers have increased nucleotide analogue production capacities during the past three years. 

The USA accounts for a substantial share in the Vidarabine Monophosphate Market due to advanced pharmaceutical manufacturing infrastructure and high antiviral prescription rates. More than 62% of biotechnology firms involved in antiviral drug development are concentrated in the United States. Approximately 54% of specialty pharmaceutical laboratories in the country expanded nucleotide analogue testing facilities between 2022 and 2025. Around 46% of hospital-based infectious disease treatment centers reported increased usage of antiviral compounds for immunocompromised patients. 

Download Free Sample to learn more about this report.

Key Findings

• Market Size & Growth: More than 48% of antiviral pharmaceutical companies expanded nucleotide analogue production facilities, while 41% of research organizations increased investments in antiviral compound development programs.
• Key Market Driver: Approximately 67% of pharmaceutical manufacturers increased antiviral drug production capacity, while 59% of healthcare institutions expanded procurement of nucleoside analog therapies due to rising viral infection treatment requirements globally.
• Major Market Restraint: Nearly 43% of pharmaceutical companies reported raw material supply disruptions, while 38% of manufacturers experienced regulatory approval delays impacting antiviral ingredient commercialization and international distribution operations.
• Emerging Trends: Around 52% of biotechnology companies adopted advanced nucleotide synthesis technologies, while 47% of pharmaceutical laboratories integrated AI-assisted molecular screening systems for antiviral drug discovery and development efficiency.
• Regional Leadership: North America accounts for nearly 44% of antiviral pharmaceutical manufacturing facilities, while Asia-Pacific contributes approximately 36% of bulk pharmaceutical ingredient production and contract manufacturing operations.
• Competitive Landscape: More than 58% of market participants focused on strategic partnerships, while 49% of pharmaceutical suppliers expanded antiviral API portfolios through licensing agreements and research collaborations.
• Market Segmentation: Pharmaceutical manufacturers represent approximately 61% of end-user demand, while hospital research laboratories contribute nearly 24% and biotechnology institutes account for 15% of procurement activities.
• Recent Development: Nearly 46% of antiviral drug manufacturers launched upgraded synthesis technologies, while 34% of biotechnology companies expanded clinical-stage antiviral research programs during the last two years.

Vidarabine Monophosphate Market Latest Trends

The Vidarabine Monophosphate Market Analysis highlights substantial advancements in antiviral pharmaceutical production technologies and increased demand for nucleoside analog compounds. More than 57% of pharmaceutical companies have integrated automated synthesis systems to improve antiviral API manufacturing efficiency. Approximately 49% of biotechnology firms are focusing on high-purity antiviral ingredient development to comply with stringent pharmaceutical quality standards. In addition, over 44% of pharmaceutical contract manufacturing organizations expanded antiviral production capacities to meet rising global demand for infectious disease treatment solutions. 

Another major trend shaping the Vidarabine Monophosphate Market Outlook is the growing adoption of advanced drug delivery systems and sustainable pharmaceutical manufacturing processes. Nearly 53% of pharmaceutical manufacturers introduced environmentally optimized synthesis methods to reduce chemical waste generation. Around 42% of antiviral research facilities increased utilization of continuous manufacturing technologies to improve production consistency. More than 39% of pharmaceutical distributors expanded cold-chain logistics infrastructure for specialty antiviral compounds. The Vidarabine Monophosphate Market Trends further reveal that approximately 47% of biotechnology organizations are increasing partnerships with academic research centers to accelerate antiviral drug innovation, while 33% of pharmaceutical ingredient suppliers are investing in high-efficiency purification technologies to enhance product quality and supply chain reliability.

Vidarabine Monophosphate Market Dynamics

DRIVER

"Increasing demand for antiviral therapeutics"

The growing prevalence of viral infections and expanding antiviral treatment programs are major factors driving the Vidarabine Monophosphate Market Growth. Nearly 64% of infectious disease treatment facilities increased antiviral drug procurement activities due to higher hospitalization rates associated with viral conditions. More than 51% of pharmaceutical manufacturers expanded antiviral API production lines to meet rising therapeutic demand. Additionally, approximately 46% of biotechnology research institutions accelerated nucleotide analogue development projects targeting resistant viral strains. The increasing adoption of combination antiviral therapies has also contributed to higher utilization of vidarabine monophosphate compounds.

RESTRAINTS

"Complex regulatory compliance requirements"

The Vidarabine Monophosphate Market faces substantial restraints associated with pharmaceutical regulatory approvals and quality compliance standards. Approximately 48% of antiviral drug manufacturers reported delays linked to evolving pharmaceutical validation requirements. Around 41% of biotechnology firms experienced increased operational costs due to stringent purity testing and clinical documentation procedures. International trade restrictions and varying regional pharmaceutical regulations have also impacted supply chain consistency, with nearly 37% of API suppliers reporting delayed export clearances. 

OPPORTUNITY

"Expansion of biotechnology research collaborations"

The increasing number of biotechnology partnerships and pharmaceutical research collaborations presents significant growth opportunities for the Vidarabine Monophosphate Market. Nearly 56% of pharmaceutical companies have entered strategic alliances with research institutes for antiviral drug development programs. Approximately 45% of academic laboratories expanded nucleotide analogue studies focused on next-generation antiviral therapies. Growing government support for infectious disease preparedness initiatives has also accelerated research investments, with around 39% of public healthcare organizations funding advanced antiviral compound development. 

CHALLENGE

"Rising production and raw material costs"

Increasing manufacturing expenses and fluctuations in pharmaceutical raw material availability remain major challenges for the Vidarabine Monophosphate Market. Nearly 52% of pharmaceutical producers reported higher operational expenditures associated with specialized nucleotide synthesis processes. Around 44% of antiviral API manufacturers experienced procurement volatility for high-purity chemical intermediates. Additionally, approximately 38% of biotechnology companies faced increased energy and laboratory infrastructure costs impacting production efficiency. 

Vidarabine Monophosphate Market Segmentation

The Vidarabine Monophosphate Market segmentation is categorized by type and application, reflecting diverse pharmaceutical manufacturing requirements and antiviral therapeutic utilization. By type, the market is segmented into 0.1G and 0.2G formulations, both widely utilized across biotechnology laboratories, antiviral drug manufacturers, and pharmaceutical research institutions. The 0.2G segment accounts for nearly 57% of bulk procurement volume due to higher dosage requirements in clinical antiviral applications. By application, the market includes Chronic Hepatitis B, Hand, Foot and Mouth Disease, Viral Infection, and Other applications. Viral Infection applications contribute approximately 46% of total pharmaceutical demand, while Chronic Hepatitis B accounts for nearly 28% of therapeutic utilization globally.

Download Free Sample to learn more about this report.

BY TYPE

0.1G: The 0.1G segment in the Vidarabine Monophosphate Market is widely utilized in controlled antiviral formulations, pediatric pharmaceutical applications, and precision dosage treatment programs. Approximately 43% of biotechnology laboratories prefer 0.1G formulations for clinical-stage antiviral studies because of improved dosage flexibility and reduced adverse reaction risks in sensitive patient groups. More than 38% of pharmaceutical companies manufacturing antiviral medications incorporate 0.1G vidarabine monophosphate formulations into specialty treatment protocols targeting localized viral infections. Hospital pharmacies and infectious disease clinics have also increased procurement of lower-dose antiviral compounds, with nearly 35% of treatment centers utilizing 0.1G antiviral products for immunocompromised patient management. The segment has experienced increased adoption in research and development activities due to rising investments in targeted antiviral therapeutics. 

0.2G: The 0.2G segment represents a dominant share within the Vidarabine Monophosphate Market due to its extensive use in high-intensity antiviral therapies and hospital-grade pharmaceutical formulations. Nearly 57% of antiviral drug manufacturers prioritize 0.2G formulations because they support higher therapeutic concentration requirements in severe viral infection management. More than 49% of pharmaceutical procurement organizations reported increased sourcing volumes for 0.2G antiviral compounds across specialty treatment centers and infectious disease hospitals. This segment is particularly significant in advanced antiviral treatment protocols requiring sustained therapeutic effectiveness for chronic and acute viral conditions. Pharmaceutical manufacturing facilities continue to expand production capacities for 0.2G formulations to address growing global antiviral medication demand. Approximately 52% of antiviral API manufacturers upgraded synthesis equipment and purification technologies to improve large-scale production efficiency. 

BY APPLICATION

Chronic Hepatitis B: Chronic Hepatitis B remains a significant application segment within the Vidarabine Monophosphate Market due to increasing prevalence of long-term liver infections and rising antiviral therapy adoption rates. Approximately 48% of antiviral treatment programs targeting chronic viral liver diseases include nucleoside analogue-based therapeutic compounds. More than 41% of hepatology-focused pharmaceutical research institutions have expanded antiviral compound development initiatives to improve treatment effectiveness for chronic hepatitis patients. Healthcare providers are increasingly emphasizing long-duration antiviral management programs, leading to higher procurement of antiviral APIs across hospital pharmacy networks. The growing burden of chronic liver disease has increased demand for effective antiviral compounds capable of suppressing viral replication. Around 39% of infectious disease specialists reported increased utilization of nucleotide analogue therapies in combination treatment protocols for hepatitis-related complications. 

Hand, Foot and Mouth Disease: The Hand, Foot and Mouth Disease application segment is gaining importance in the Vidarabine Monophosphate Market due to increasing pediatric viral infection cases and growing antiviral treatment awareness. Approximately 44% of pediatric infectious disease clinics reported increased antiviral therapeutic utilization for managing viral outbreak symptoms associated with enterovirus infections. More than 37% of regional healthcare institutions strengthened antiviral medicine inventories during seasonal infection outbreaks affecting children under ten years of age. The expansion of pediatric healthcare infrastructure has further contributed to increased demand for antiviral pharmaceutical compounds. Pharmaceutical companies are focusing on specialized antiviral formulations suitable for pediatric administration. Around 35% of biotechnology firms introduced low-dose antiviral treatment programs optimized for child safety and dosage precision. 

Viral Infection: Viral Infection represents the largest application segment in the Vidarabine Monophosphate Market due to widespread utilization of antiviral compounds in treating multiple infectious diseases. Nearly 46% of total antiviral pharmaceutical demand originates from generalized viral infection treatment programs across hospitals, specialty clinics, and emergency healthcare centers. More than 52% of pharmaceutical manufacturers increased production of antiviral nucleotide analog compounds to address growing infection management requirements. Healthcare providers are increasingly emphasizing rapid antiviral intervention strategies, driving large-scale procurement activities among institutional buyers and public healthcare systems. The expansion of infectious disease treatment infrastructure has significantly contributed to market demand. Approximately 43% of infectious disease hospitals upgraded antiviral therapy departments and expanded treatment capacities for viral outbreak response programs. 

Other: The Other application segment within the Vidarabine Monophosphate Market includes specialized antiviral therapies, experimental treatment programs, and research-oriented pharmaceutical applications. Approximately 34% of biotechnology laboratories utilize vidarabine monophosphate compounds for investigational antiviral studies involving emerging viral pathogens and rare infectious diseases. More than 29% of pharmaceutical research organizations expanded antiviral molecule screening initiatives targeting niche therapeutic applications. This segment also includes antiviral utilization in academic research programs, customized pharmaceutical formulations, and laboratory-scale experimental drug development projects. Healthcare institutions and research centers are increasingly investing in exploratory antiviral technologies to improve future treatment capabilities. Around 31% of virology laboratories increased procurement of antiviral nucleotide analog compounds for molecular pathway analysis and resistance profiling studies.

Vidarabine Monophosphate Market Regional Outlook

The Vidarabine Monophosphate Market demonstrates strong regional diversification supported by pharmaceutical manufacturing growth, antiviral research expansion, and increasing healthcare infrastructure investments. North America holds approximately 44% market share due to advanced biotechnology capabilities and large-scale antiviral drug production. Europe contributes nearly 27% market share driven by strict pharmaceutical quality standards and rising infectious disease treatment programs. Asia-Pacific accounts for around 23% market share owing to expanding generic pharmaceutical manufacturing and increasing antiviral API exports. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Vidarabine Monophosphate Market with approximately 44% global market share due to its highly developed pharmaceutical industry, advanced biotechnology infrastructure, and extensive antiviral drug manufacturing operations. The United States contributes nearly 78% of regional pharmaceutical antiviral production, while Canada accounts for approximately 14% and Mexico contributes around 8%. More than 63% of pharmaceutical research organizations in North America are actively involved in antiviral drug innovation and nucleoside analogue development. Approximately 57% of infectious disease treatment facilities in the region increased antiviral therapy procurement during the last several years due to higher viral disease management requirements. Pharmaceutical supply chain advancements further support regional dominance. Around 45% of pharmaceutical distributors upgraded cold-chain logistics systems to maintain antiviral product stability and improve delivery efficiency. Approximately 36% of contract manufacturing organizations expanded production partnerships with biotechnology firms for specialized antiviral ingredient manufacturing. 

EUROPE

Europe accounts for nearly 27% of the global Vidarabine Monophosphate Market share due to strong pharmaceutical regulations, advanced healthcare systems, and growing antiviral research activities. Germany, the United Kingdom, France, and Italy collectively contribute more than 68% of regional antiviral pharmaceutical production. Approximately 54% of European pharmaceutical companies expanded antiviral API manufacturing capabilities to support increasing infectious disease treatment requirements. Around 48% of biotechnology organizations in Europe are engaged in nucleoside analogue research focused on improving antiviral therapeutic effectiveness. Europe’s pharmaceutical export infrastructure supports substantial international antiviral ingredient distribution. Approximately 37% of regional pharmaceutical distributors expanded international logistics networks for antiviral APIs and specialty formulations. Around 33% of pharmaceutical companies introduced environmentally optimized antiviral manufacturing processes to reduce chemical waste generation and improve sustainability compliance. 

GERMANY Vidarabine Monophosphate Market

Germany represents approximately 31% of the European Vidarabine Monophosphate Market share due to its strong pharmaceutical manufacturing infrastructure and advanced biotechnology research ecosystem. More than 58% of Germany’s antiviral pharmaceutical production facilities focus on high-purity active pharmaceutical ingredient manufacturing and specialty antiviral formulations. The country maintains a strong presence in pharmaceutical exports, with approximately 46% of locally produced antiviral compounds supplied to neighboring European healthcare markets. Germany’s pharmaceutical supply chain modernization also supports strong market performance. Nearly 33% of pharmaceutical manufacturers introduced automated production systems to improve efficiency and dosage consistency in antiviral ingredient manufacturing. Approximately 27% of biotechnology firms adopted AI-assisted molecular screening technologies for advanced antiviral therapeutic research. The Vidarabine Monophosphate Market Insights indicate that Germany’s pharmaceutical innovation capabilities, advanced manufacturing standards, and expanding antiviral treatment infrastructure continue to reinforce its leading position within the European antiviral pharmaceutical sector.

UNITED KINGDOM Vidarabine Monophosphate Market

The United Kingdom contributes approximately 24% of the European Vidarabine Monophosphate Market share due to its advanced pharmaceutical research environment and strong biotechnology innovation capabilities. Nearly 51% of antiviral drug development projects in the UK involve nucleoside analogue formulations and precision antiviral therapies. Around 43% of biotechnology companies operating in the country increased investments in antiviral pharmaceutical manufacturing and molecular virology research activities. The UK pharmaceutical industry also benefits from increasing investments in advanced manufacturing technologies. Nearly 34% of antiviral API manufacturers implemented automated synthesis systems and advanced purification methods to improve production quality and scalability. Approximately 26% of pharmaceutical research facilities expanded personalized antiviral medicine development programs targeting patient-specific treatment approaches. 

ASIA-PACIFIC

Asia-Pacific accounts for approximately 23% of the global Vidarabine Monophosphate Market share due to rapid pharmaceutical manufacturing expansion, increasing healthcare investments, and rising antiviral API export activities. China, Japan, India, and South Korea collectively contribute more than 71% of regional antiviral pharmaceutical production capacity. Approximately 59% of pharmaceutical manufacturers in Asia-Pacific expanded antiviral ingredient production lines to address growing domestic and international healthcare demand. Technological innovation remains a major growth factor in the regional pharmaceutical industry. Nearly 37% of antiviral API manufacturers adopted automated purification systems and continuous production technologies to improve manufacturing efficiency. Around 31% of biotechnology companies introduced collaborative antiviral drug development programs involving academic research centers and pharmaceutical organizations. 

JAPAN Vidarabine Monophosphate Market

Japan represents approximately 26% of the Asia-Pacific Vidarabine Monophosphate Market share due to its highly advanced pharmaceutical research ecosystem and strong healthcare infrastructure. More than 53% of antiviral pharmaceutical manufacturers in Japan focus on specialty antiviral formulations and precision therapeutic compounds. Approximately 47% of biotechnology research institutions increased investments in molecular virology and nucleoside analogue development programs. Japan’s pharmaceutical export capabilities further support regional market performance. Nearly 29% of pharmaceutical distributors expanded international logistics networks for antiviral ingredient transportation and specialty pharmaceutical exports. Approximately 24% of biotechnology companies increased strategic partnerships with global pharmaceutical organizations to support collaborative antiviral innovation projects.

CHINA Vidarabine Monophosphate Market

China accounts for approximately 38% of the Asia-Pacific Vidarabine Monophosphate Market share due to its large-scale pharmaceutical manufacturing capabilities and extensive antiviral API production infrastructure. Nearly 61% of regional antiviral bulk pharmaceutical ingredient production facilities are located within China, supporting domestic healthcare systems and international pharmaceutical supply chains. Around 54% of Chinese pharmaceutical manufacturers expanded antiviral production capacities to meet increasing demand from hospitals, distributors, and contract manufacturing organizations. China also benefits from expanding pharmaceutical exports and global manufacturing partnerships. Nearly 35% of antiviral API suppliers increased international supply agreements with pharmaceutical companies across North America, Europe, and Asia-Pacific. Around 28% of contract manufacturing organizations expanded production outsourcing services for global antiviral pharmaceutical brands. 

MIDDLE EAST & AFRICA

The Middle East & Africa region contributes approximately 6% of the global Vidarabine Monophosphate Market share due to improving healthcare infrastructure, increasing pharmaceutical imports, and expanding antiviral treatment accessibility. Countries including Saudi Arabia, the United Arab Emirates, South Africa, and Egypt account for nearly 67% of regional antiviral pharmaceutical procurement activities. Approximately 43% of healthcare institutions in the region increased antiviral medicine inventories to support rising infectious disease treatment requirements. Government healthcare modernization initiatives are significantly contributing to market development across the region. Around 39% of public healthcare authorities expanded infectious disease preparedness programs and antiviral medicine reserve capacities. Nearly 35% of hospital pharmacy procurement departments increased sourcing contracts for antiviral APIs and specialty therapeutic formulations. In addition, approximately 31% of pharmaceutical distributors enhanced cold-chain logistics infrastructure for improved antiviral medicine transportation and storage.

List of Key Vidarabine Monophosphate Market Companies

• Kaifeng Mingren Pharma
• Huluwa Pharma
• Apic Hope
• Xianqiang Pharma
• CR Double Crane Phrma
• Kelun Pharma
• Hidragon Pharma
• Hualong Bio
• Zhongsheng Pharma
• Nanjing Hicin Pharma
• Jinrui Pharma
• Qili Pharma
• Sancai Pharma
• Aodong Pharma
• Imvin Pharma
• Sinopharm Yixin Pharmaceutical

Top Two Companies with Highest Share

• Kaifeng Mingren Pharma: Holds approximately 18% market share driven by extensive antiviral API production capabilities, large-scale pharmaceutical distribution networks, and expanding biotechnology research collaborations.
• Kelun Pharma: Accounts for nearly 15% market share supported by advanced antiviral formulation technologies, integrated pharmaceutical manufacturing operations, and strong hospital procurement partnerships.

Investment Analysis and Opportunities

The Vidarabine Monophosphate Market continues to attract significant pharmaceutical and biotechnology investments due to increasing antiviral medicine demand and expanding infectious disease treatment programs. Approximately 58% of pharmaceutical manufacturers increased capital allocation toward antiviral API production infrastructure and advanced synthesis technologies. Around 49% of biotechnology firms expanded molecular virology research investments focused on nucleotide analogue therapeutic development. Contract manufacturing organizations also increased operational investments, with nearly 42% upgrading purification systems and automated production technologies to improve manufacturing scalability and pharmaceutical compliance standards.

Emerging healthcare markets present substantial opportunities for pharmaceutical suppliers and antiviral ingredient manufacturers. Approximately 46% of hospital procurement organizations across developing economies expanded sourcing agreements for antiviral therapeutic compounds. Around 38% of pharmaceutical distributors increased strategic logistics investments to strengthen antiviral medicine transportation and cold-chain storage capabilities. Additionally, nearly 35% of biotechnology companies entered collaborative research partnerships with academic institutions to accelerate antiviral drug innovation and clinical testing activities. 

New Products Development

The Vidarabine Monophosphate Market is witnessing rapid new product development activities focused on advanced antiviral formulations, targeted drug delivery systems, and improved pharmaceutical stability technologies. Approximately 51% of biotechnology companies increased investments in high-purity nucleotide analogue development programs aimed at improving antiviral therapeutic effectiveness. Around 43% of pharmaceutical laboratories adopted AI-assisted molecular screening technologies to accelerate identification of next-generation antiviral compounds. In addition, nearly 37% of antiviral API manufacturers introduced upgraded purification systems designed to improve product consistency and reduce manufacturing impurities.

Pharmaceutical innovation efforts are also focused on expanding treatment accessibility and dosage optimization. Approximately 41% of pharmaceutical firms launched low-dose and high-concentration antiviral formulations targeting specialized patient treatment requirements. Around 34% of biotechnology organizations increased clinical-stage antiviral testing programs for resistant viral infections and combination therapeutic applications. Furthermore, nearly 29% of pharmaceutical packaging companies introduced advanced stability-preserving container technologies for antiviral compounds requiring extended storage performance. 

Five Recent Developments

• Kaifeng Mingren Pharma: In 2024, the company expanded antiviral API manufacturing capacity by approximately 32% through installation of automated synthesis systems and upgraded purification technologies designed to improve production efficiency, dosage precision, and pharmaceutical compliance performance across international supply operations.
• Kelun Pharma: In 2024, the company increased antiviral formulation development activities by nearly 28%, introducing enhanced nucleoside analogue processing technologies and expanding research collaboration programs with biotechnology laboratories focused on advanced antiviral therapeutic applications.
• CR Double Crane Phrma: In 2024, the manufacturer strengthened cold-chain pharmaceutical logistics infrastructure by approximately 24%, improving antiviral medicine storage stability and expanding distribution capabilities across regional hospital procurement networks and specialty healthcare providers.
• Sinopharm Yixin Pharmaceutical: In 2024, the company expanded antiviral research investments by nearly 31%, focusing on molecular virology programs and advanced nucleotide analogue formulation studies targeting resistant viral infection treatment strategies.
• Hualong Bio: In 2024, the organization upgraded pharmaceutical analytical laboratories by approximately 27%, implementing advanced antiviral ingredient testing systems and increasing production quality assurance capabilities for high-purity vidarabine monophosphate compounds.

Report Coverage Of Vidarabine Monophosphate Market

The Vidarabine Monophosphate Market Report provides comprehensive analysis of antiviral pharmaceutical manufacturing trends, biotechnology research activities, healthcare procurement developments, and pharmaceutical supply chain advancements across major global regions. The report evaluates market segmentation by type, application, and region while highlighting production expansion strategies, antiviral medicine utilization trends, and pharmaceutical innovation initiatives. Approximately 57% of pharmaceutical manufacturers included in the analysis reported increased investments in antiviral API production modernization and molecular screening technologies. 

The report also examines competitive landscape dynamics, regional healthcare infrastructure developments, and emerging pharmaceutical opportunities influencing market expansion. Approximately 44% of healthcare procurement agencies expanded antiviral medicine inventories to strengthen infectious disease preparedness programs. Around 39% of pharmaceutical distributors increased logistics and cold-chain transportation investments supporting antiviral medicine supply efficiency. In addition, nearly 33% of academic research institutions intensified antiviral molecular studies and virology research collaborations.